

J.P. Morgan 2022 Virtual Healthcare Conference

January 2022



Safe Harbor Statement

Forward-Looking Statements

This presentation includes forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to management. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements regarding our positioning to successfully manage the ongoing impact of COVID-19, including variants, and the associated economic uncertainty on our business; the timing of client decisions; our financial outlook for the fourth quarter and full year 2021, including our expected utilization rates and mix; our ability to retain existing clients and acquire new clients; and our business strategy, plans, goals and expectations concerning our market position, future operations, and other financial and operating information, including our topline growth and margin expansion. The words "may," "believes," "intends," "seeks," "anticipates," "estimates," "estimates," "estimates," "could," "will," "future," "project," and the negative of these or similar terms and phrases are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, without limitation, risks related to the orgoing impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of fertility procedures and other impacts to the business; failure to meet our publicly announced guidance or other expectations about our business; competition in the market in which we operate; our history of operating losses and ability to sustain profitability in the future; our limited operating history and the difficulty in predicting our future results of operatings; our ability to attract and retain clients and increase the adoption of services within our client base; the loss of any of our largest client accounts; changes in the technology industry; changes in the health insurance market; negative publicity in the health benefits industry; lags, failures or security breaches in our computer systems or those of our ventoers; a significant change in the utilization of our solutions; our ability to offer high-quality support; positive references from our existing clients; our ability to develop and expand our dustry or the United States economy, such as conditions resulting from outbreaks of contagious diseases, including COVID-19 and variants; reductions in employee benefits spending; seasonal fluctuations in our inability to attract and retain members of our management team, key employees, or other qualified personnel; our ability to attract and retain members of our management team, key employees, or other qualified personnel; our ability to maintain our centeries; risks related to potential sales to government entities; our ability to protect our int

Forward-looking statements represent our management's beliefs and assumptions only as of the date of our November 4, 2021 press release and are not being confirmed or updated herein. Our actual future results could differ materially from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons. Actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Non-GAAP Financial Measures

In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), this presentation and the accompanying tables include the non-GAAP financial measures Adjusted EBITDA and Adjusted EBITDA and Adjusted EBITDA and Adjusted EBITDA margin. Adjusted EBITDA and Adjusted EBITDA margin are supplemental financial measures that are not required by, or presented in accordance with, GAAP. We believe that Adjusted EBITDA and Adjusted EBITDA margin, when taken together with our GAAP financial results, provides meaningful supplemental information regarding our operating performance and facilitates internal comparisons of our historical operating performance on a more consistent basis by excluding certain items that may not be indicative of our business, results of operations or outlook. In particular, we believe that the use of Adjusted EBITDA and Adjusted EBITDA margin are helpful to our investors as they are measures used by management in assessing the health of our business, determining incentive compensation, evaluating our operating performance, and for internal planning and forecasting purposes.

Adjusted EBITDA is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Some of the limitations of Adjusted EBITDA include: (1) it does not properly reflect capital commitments to be paid in the future; (2) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures; (3) it does not consider the impact of stock-based compensation expense; (4) it does not reflect other non-operating expenses, including other income and interest (income) expense, net; (5) it does not reflect tax payments that may represent a reduction in cash available to us; and (6) it does not include legal fees associated with a vendor arbitration. In addition, our Adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate Adjusted EBITDA alongside other financial performance measures, including our net income from continuing operations and other GAAP results.

We calculate Adjusted EBITDA as net income, adjusted to exclude depreciation and amortization; stock-based compensation expense; other income; interest (income) expense, net; provision for income taxes; and legal fees associated with a vendor arbitration we calculate Adjusted EBITDA margin as Adjusted EBITDA divided by revenue. Please see "Reconciliation of GAAP to Non-GAAP Financial Measures" in the appendix of this presentation.

Progyny's Investment Thesis

- The fertility market is:
 - Large and rapidly growing
 - Supported by multiple tailwinds
 - · Resilient during the pandemic
- Despite this, the market has been poorly served by the managed care providers

- Progyny fills the gaps unaddressed by the traditional carriers, producing:
 - Better outcomes
 - Happier employees
 - More efficient use of employers' healthcare spend
- We have a six-year trend since inception of strong top-line growth and margin expansion, with positive EBITDA and a high rate of cash flow conversion
- We are at a very early stage of penetrating our addressable market

Progyny has strengthened its competitive advantages to become the **brand of choice** among large, self-insured employers



Fertility Market Growth at 9.4% CAGR¹ over last 10 Years


Growth of 9.4% CAGR¹ in Assisted Reproductive Technology cycles has been aided by ongoing favorable tailwinds:

- Over the last ten years, people deferring family building:
 - Natural birth rates declining at 1.1% CAGR²
 - Birth rates for women 15 to 34 declined at 1.7% CAGR²
 - Birth rates for women 35+ increased at 2.2% CAGR²
 - Average age of a woman using fertility services is 36¹
 - Fueling need for fertility preservation
- Employers increasingly beginning to offer some form of fertility benefit
 - Coverage in most cases is limited and, in many cases, exhausted prior to achieving a successful outcome
- Alternative paths to pregnancy more common
- 1. CDC, 2019 National Summary and Clinic Data Sets, published in 2021, and 2010 National Summary and Clinic Data Sets, published in 2012
- 2. National Vital Statistic Reports, National Center for Health Statistics, 2021 and 2012 (vol 70 no 2 and vol 61 no 1, respectively)
- 3. 3rd party studies from Mercer and Willis Towers Watson

Percent of Large Employers with a Fertility Benefit³ 2015 Today 2023 (Est.) 2015 • Today 023 (Est.) 5 • Of Employers With a Fertility Benefit • % of Employers Without a Fertility Benefit

The Fertility Marketplace Potential

- Infertility is a highly prevalent disease, affecting 1 in 8 couples, or 12.5%, of the population in child-bearing years
- The current size of the fertility market has been understated because of insufficient employer sponsorship
- Only 2% of US babies are from assisted reproductive technologies
 - Compares to 10% in other countries with broad coverage in fertility services
- Progyny has been helping to grow the overall market by expanding access to high quality care



Despite Our Rapid Growth, We Remain in Earliest Stages of Penetrating our Core Market

Large, Self-Insured Employers


- There are 8,000 companies in the US with at least 1,000 employees
- Only ~3% are our clients today

開開			
開開			
開開			

Note: each icon represents 125 companies

Covered Lives

- The companies in our target market represent ~75M covered lives
- We have ~5% of those under contract



Note: each icon represents 1.5M covered lives

Progyny Member Utilization Resilient During COVID


- As compared to other areas of healthcare, Progyny's utilization rates largely recovered sooner and with more velocity, due to:
 - The time sensitive nature of treatment

7

• The resilience of fertility patients in their desire to pursue care

Progyny's Quarterly Female Utilization Rate

Consistent range of utilization in all but two of the past thirteen quarters



Progyny Was Built to Solve Gaps in Fertility Coverage

Traditional carriers and other alternatives continue to fall short:

Inferior pregn rates in fertilit	•	High medical preventable I high-risk pres multiple birt	VF-related gnancies and	Patient stress, mental health costs and employee absenteeism due to inadequate or unsupported fertility journeys					
	Inequity and I inclusion in th fertility benefi	e company's	Poor recruitm retention due family building						



Progyny Redefined the Market

Progyny redefined fertility benefit management by leading with the member experience, partnering with world class providers, managing all aspects of a comprehensive solution, and delivering superior outcomes - at scale!

Coordinated Member Experience

- Flexible, easy to understand Smart Cycle design, including coverage for the latest technologies, to support diverse family-building needs
- Integrated pharmacy solution
- High-touch, high support, extensive education

Active Network Management

- Rigorous inclusion standards
- Data-driven active provider management

Proven and Predictable Outcomes

- Industry-leading superior clinical outcomes since our inception
- Medical and pharmacy savings
- Multiples and high-risk maternity cost avoidance

Powered by Data


- Data-driven decision making across all aspects of solution
- Detailed, transparent quarterly and annual reporting



Progyny is the <u>only</u> fullymanaged fertility solution and no competitor has all these elements in their program



Progyny Leads the Market in Patient Outcomes




Out of network clinic average | National Average | In-network clinic average for all patients (includes non-Progyny patients at clinic) | Only Progyny Patients

Note: Progyny represents Progyny in-network provider clinic averages for Progyny members only based on the 12-month period ended December 31, 2020. For each Progyny outcome presented, the p-value when compared to the national average is <0.0001.


¹ Calculated based on the Society for Assisted Reproductive Technology, or SART, 2018 National Summary Report, finalized in 2021

² Calculated based on CDC, 2019 National Summary and Clinic Data Sets, published i


The Value Created by Favorable Outcomes




Progyny Has Become the Provider of Choice for Fertility Benefits Management



Progyny Has Become the Provider of Choice for Fertility Benefits Management



Progyny Has Become the Provider of Choice for Fertility Benefits Management



Our Growing List of Clients Reflects the Universal Need for Fertility

We have built a significantly diversified client base, reflecting a broad-cross section in terms of:

- Company sizes
- Number of industries
- Geographic locations





Success with New Client Acquisition and Retention



Expansion Opportunities with Existing Clients

We have multiple pathways to grow with our existing clients:

Via organic growth:

 Many of our clients continue to expand their workforce, adding to our covered lives

Via the upselling of new services:

- **One-third** of our clients added services for 2022, including:
 - Progyny Rx
 - More Smart Cycles
 - Surrogacy and adoption reimbursement




Progyny Rx Launched in 2018

For every client who takes Progyny Rx, the revenue opportunity is 50% bigger


- Integrated pharmacy experience with single authorization
- Avoids missed or delayed treatment cycles
- White glove service reduces anxiety of medication administration and storage
- Provides significant specialty medication savings

New Client Take Rate of Progyny Rx By Selling Season





We are Scaling the Business Rapidly and Profitably




1. As per the press release issued as of November 4, 2021

2. See appendix for a reconciliation of Adjusted EBITDA

19

3. CAGR calculated using the midpoint of the range as per the press release issued as of November 4, 2021

Significant Runway for Ongoing Growth





J.P. Morgan 2022 Virtual Healthcare Conference

January 2022



Appendix: Reconciliation of GAAP to Non-GAAP Financial Measures

(in thousands)	Year Ended December 31, 2016 2017 2018 2019 2020								Reconciliation of Anticipated Net Income to Anticipated Adjusted EBITDA for the Year Ended December 31, 2021 ¹ Low High				
Net (loss) income from continuing operations	\$	(11,833)	\$	(12,456)	\$	(5,116)	\$	(8,569)	\$ 46,459	\$	51,500	\$	54,100
Add:													
Depreciation and amortization		1,700		1,559		1,883		2,135	1,906		1,400		1,300
Stock-based compensation expense		728		1,559		2,997		5,061	12,821		31,100		30,600
Other (income) expense, net		1,065		740		497		58	(331)		(300)		(300)
Convertible preferred stock warrant valuation adjustment		(741)		714		2,944		18,176	-		-		-
Provision (benefit) for income taxes		(3,028)		(3)		(1,777)		12	(37,780)		(14,700)		(15,200)
Settlement cost and legal fees associated with a vendor arbitration		-		-		-		1,319	9,318		-		-
Non-deferred IPO Costs		-		-		-		150	-		-		-
Adjusted EBITDA	\$	(12,109)	\$	(7,887)	\$	1,428	\$	18,342	\$ 32,393	\$	69,000	\$	70,500

1. Reflects the guidance ranges provided in our November 4, 2021 press release and is as of November 4, 2021; Net income and Adjusted EBITDA ranges do not reflect any estimate for other potential activities and transactions, nor do they contemplate any discrete income tax items, including the income tax impact related to equity compensation activity.